Cardiac Marker Testing Market: Emerging Trends and Global Future Forecast

The report Cardiac Marker Testing Marketanalyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

This report studies the global Cardiac Marker Testing Market over the forecast period of 2016 to 2021. The market is expected to reach ~USD 3.50 Billion by 2021, at a CAGR of 8.8% from 2016 to 2021. 

Download PDF Brochure:-

A number of factors such as growing incidences of cardiovascular diseases, the rapidly increasing geriatric population, growing funding from public–private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers are fueling the growth of the cardiac marker testing market.

Based on type, the global cardiac marker testing market is divided into six segments, namely, troponin I and T, CK-MB, BNP or NT-proBNP, Myoglobin, hsCRP, and other biomarkers. The other biomarkers segment includes galectin-3, H-FABP, myeloperoxidase, ischemia-modified albumin, and homocysteine.

On the basis of product, the global cardiac marker testing market is segmented into reagents and kits and instruments. The instruments section is further segmented on the basis of method, namely, chemiluminescence, immunofluorescence, ELISA, and immunochromatography. On the basis of disease, the cardiac marker testing market is segmented into myocardial infarction and congestive heart failure. On the basis of type of testing, the cardiac marker testing market is segmented into laboratory testing and point-of-care testing.

As of 2016, North America held the largest share of the global cardiac marker testing market, followed by Europe. However, the Asia-Pacific market is expected to register the highest CAGR of 11.7% from 2016 to 2021.


Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (U.S.), Siemens AG (Germany), Danaher Corporation (U.S.) Alere, Inc. (U.S.), bioMérieux SA (France), LSI Medience Corporation (a subsidiary of Mitsubishi Chemical Holdings Corporation, Japan), Ortho Clinical Diagnostics (a subsidiary of The Carlyle Group, U.S.), Randox laboratories Ltd (U.K.), and Guangzhou Wondfo Biotech Co., Ltd. (Wondfo) (China) are some of the key players operating in the global cardiac marker testing market.